Assyro AI

Orange Book product · Brand (NDA)

LOKELMA

SODIUM ZIRCONIUM CYCLOSILICATE

Brand (NDA)NDA 207078RX ASTRAZENECA

At a glance

May 18, 2018

Approved

Brand (NDA)

Application

Not listed

TE code

13

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 18, 2018

    8 yr 2 mo ago

  2. Today

  3. Patent 10398730 expires

    Listed method-of-use patent (U-2312) expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  4. Patent 10413569 expires

    Listed drug substance patent expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  5. Patent 11406662 expires

    Listed drug substance patent expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  6. Patent 8808750 expires

    Listed method-of-use patent (U-2312) expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  7. Patent 9844567 expires

    Listed method-of-use patent (U-2312) expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  8. Patent 9861658 expires

    Listed method-of-use patent (U-2312) expiration.

    Feb 10, 2032

    in 5 yr 9 mo

  9. Patent 8802152 expires

    Listed drug substance patent expiration.

    Apr 19, 2032

    in 5 yr 11 mo

  10. Patent 10695365 expires

    Listed drug substance patent expiration.

    Oct 22, 2033

    in 7 yr 5 mo

  11. Patent 8877255 expires

    Listed drug substance patent expiration.

    Oct 22, 2033

    in 7 yr 5 mo

  12. Patent 9913860 expires

    Listed drug substance patent expiration.

    Oct 22, 2033

    in 7 yr 5 mo

  13. Patent 10300087 expires

    Listed drug substance patent expiration.

    Oct 14, 2035

    in 9 yr 5 mo

  14. Patent 11738044 expires

    Listed method-of-use patent (U-2312) expiration.

    Oct 14, 2035

    in 9 yr 5 mo

  15. Patent 9592253 expires

    Listed drug substance patent expiration.

    Oct 14, 2035

    in 9 yr 5 mo

Pharmaceutical detail

Active ingredient

SODIUM ZIRCONIUM CYCLOSILICATE

Strength

10GM/PACKET

Dosage form

FOR SUSPENSION

Route

ORAL

TE code

Not listed

Application

NDA 207078

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (13)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10398730Feb 10, 2032in 5 yr 9 mo
U-2312
10413569Feb 10, 2032in 5 yr 9 mo
Substance
11406662Feb 10, 2032in 5 yr 9 mo
Substance
8808750Feb 10, 2032in 5 yr 9 mo
U-2312
9844567Feb 10, 2032in 5 yr 9 mo
U-2312
9861658Feb 10, 2032in 5 yr 9 mo
U-2312
8802152Apr 19, 2032in 5 yr 11 mo
Substance
10695365Oct 22, 2033in 7 yr 5 mo
Substance
8877255Oct 22, 2033in 7 yr 5 mo
Substance
9913860Oct 22, 2033in 7 yr 5 mo
SubstanceU-2312
10300087Oct 14, 2035in 9 yr 5 mo
SubstanceU-2312
11738044Oct 14, 2035in 9 yr 5 mo
U-2312
9592253Oct 14, 2035in 9 yr 5 mo
SubstanceU-2312
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.